HealthCap

Updated on Dec 23, 2023

Edit

Comment

Products Venture Capital Website www.healthcap.eu Type of business Private Headquarters Stockholm, Oslo, Lausanne		Number of employees ~25 (2015) Founded 1996 Total assets 1 billion EUR

Industry Private Equity and Venture Capital

Healthcap mycompany

HealthCap is a specialized provider of venture capital within life sciences. HealthCap invests in innovative companies with focus on therapeutics. HealthCap has invested in over 100 companies since inception and completed initial public offerings of more than 35 companies. HealthCap has offices in Stockholm, Oslo and Lausanne.

Healthcap risk management and liability insurance

History

The firm was founded in 1996 by Björn Odlander and Peder Fredrikson and the first fund was started the same year. As of 2012, HealthCap has established six funds. The first five funds have financed 91 companies, 35 of the companies were start-ups. The most recent fund, HealthCap VI, was established in the spring of 2011. In 2015, HealthCap had approximately 25 employees out of which eleven are partners. The team combines venture capital investing experience with competencies and work experiences from small as well as large companies across the health care industry, spanning disciplines of scientific research, drug development, clinical practice, investment banking, and industry management.

Assets under management

HealthCap has raised six main funds. HealthCap IV-VI are Delaware Limited Partnerships with a Swiss general partner. Investors in HealthCap funds include, among others, Skandia Life Insurance, the 4th and 6th Swedish National Pension Funds, The Kresge Foundation, Mayo Clinic, Northwestern University, University of Michigan, Vanderbilt University and Washington University. In 2012, HealthCap had committed capital exceeding €900 million.

Investments

HealthCap invests in companies developing disruptive technologies that hold the potential to change clinical practice. Over the years the portfolio companies have developed more than 20 pharmaceutical products and over 40 med-tech products to the market. Many of these products, such as Firazyr®, Xofigo®, Tracleer®, are breakthrough therapies addressing life-threatening diseases. Examples of technologies financed by HealthCap are

Endoscopic Lung volume reduction surgery developed by Pulmonx whereby open thoracic surgery can be avoided in treatment of emphysema.

Alpharadin developed by Algeta for treatment of bone metastasis in prostate cancer.

Trans-femoral Aortic valve replacement developed by CoreValve that evades the need for open heart surgery when replacing a malfunctioning heart valve.

Measurement of exhaled nitric oxide for monitoring of asthma developed by Aerocrine.

Injectable synthetic bone substitute, Cerament, to enhance bone remodeling and fracture healing developed by BoneSupport AB.

Novel cancer therapies developed by Oncos Therapeutics.

Bioengineered organs and tissues developed by Tengion, based on experiments on autologous tissue engineering technology and optimal biomaterials.

Studying and advancing the clinical development of WTX101, or bis-choline tetrathiomolybdate, by Wilson Therapeutics. WTX101 is an orphan drug used as a therapy of Wilson's disease, an autosomal recessive genetic disorder in which copper accumulates in tissues and leads to neurological or psychiatric symptoms and liver disease.

References

HealthCap Wikipedia

(Text) CC BY-SA